MHC-II play an important part in antigen presentation to CD4+ T-lymphocytes and anti-tumor immunity, increasing evidence indicates that tumor-specific MHC-II related to favorable outcomes in patients with cancer, including those treated with immunotherapies, and with tumor rejection in murine models (Axelrod et al., 2018). The gene discussed is CD4; the disease is cancer.